ReviewProbiotics and antimicrobial proteins2026
Synbiotics: An Emerging Frontier in Infectious Diseases Control.
Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Microbiotherapy: an emerging adjunct for burn wound healing.Frontiers in cellular and infection microbiology · 2026Review
- The Gut Microbiota-NLRP3 Inflammasome Axis in Chronic Heart Failure: Mechanisms Across Heart Failure Phenotypes and Therapeutic Perspectives.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The human gut microbiome is critical in promoting human health in many aspects, like facilitating nutrient absorption, digestion, immune system regulation, and protecting against pathogens. Gut microbiota dysbiosis is associated with the pathogenesis of several infectious diseases. In this context, a combination of prebiotics and probiotics as synbiotics is emerging as a popular approach for managing immune and gastrointestinal health. Synbiotics have exhibited considerable potency in restoring eubiosis via modulating the gut microbiome. The dietary supplementation of synbiotics has shown promising results in treating infectious diseases like hepatitis, gastroenteritis, dental caries, and sepsis. Synbiotics antagonise pathogens by maintaining gut microbiota homeostasis, competing with pathogenic microorganisms for adhesion and nutrition, producing antimicrobial compounds, and stimulating immunomodulatory cells in vivo. The present article has been conceptualised to understand the potential of synbiotics as an alternative or adjunct to antibiotics in managing infectious diseases. Furthermore, it elaborates on the different formulations of synbiotics available for clinical use and their mode of action. Challenges associated and recent approaches to improve the efficacy of these therapeutics have also been addressed.
Indexed as
Identifiers
40802226What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.